Practical guidance on a complex problem
STUDY: O’Hara-Veintimilla K et al, Age and Ageing 2026;
STUDY TYPE: Systematic review
FUNDING: Norwegian Health Association; Norwegian government (Helse Vest)
Background
Benzodiazepines and Z-drugs are widely prescribed to older adults despite well-documented risks — falls, fractures, respiratory illness, cognitive impairment, and delirium. This review looks for the most successful deprescribing strategies.
The Study
- Thirty studies involving roughly 11,000 adults aged 65 and older, testing various desprescribing strategies.
- Settings included primary care, nursing homes, and hospitals across North America, Europe, and Oceania.
- Follow-up ranged from weeks to two years.
Structured gradual tapering was the most effective strategy, achieving discontinuation or major dose reduction in 60–82% of participants. Withdrawal symptoms were common but mild and transient. No study reported seizures, delirium, or hallucinations.
Patient-directed education (mailed materials, brief counseling) produced more modest but consistent results, with discontinuation rates of 22–27% at six months.
Clinician-led and system-level approaches improved prescribing quality at the population level but showed variable individual results.
Adjunctive meds for withdrawal added little.
Practice Implications
- Gradual, individualized dose reduction is what works
- If your older patient has been on a benzodiazepine for months or years, start the conversation. Send educational materials first if they’re not ready to taper. When they are, reduce the dose by 5–25% every few weeks, monitor for anxiety or insomnia, and don’t rush it.
- For patients with severe psychiatric comorbidity or palliative care needs, continued use may still be appropriate.
— Chris Aiken, MD
Director, Psych Partners
Editor in Chief, Carlat Psychiatry Report







